Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates NBP Bearish with a Setup Score of 31, net conviction 23, actionability 42. How the Setup Score works →
| Total Setup Score | 31 |
|---|---|
| Directional Bias | Bearish |
| Net Conviction | 23 |
| Actionability | 42 (in range) |
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN… Read full Trend Edge analysis →
| Current Price | $1.37 |
|---|---|
| Market Cap | $155M |
| Float | 64.4M |
| Shares Outstanding | 115.6M |
| P/E (Forward) | 2.68 |
| Price/Sales (TTM) | 25.39 |
| Dividend Rate | None |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $1.54B | $471M | $1.54B | $168M |
| 2021 | $88.0M | -$2.33B | $41.6M | -$2.06B |
| 2022 | -$10.7M | -$968M | -$10.7M | -$356M |
| 2023 | $4.5M | -$1.47B | $4.5M | -$344M |
| 2024 | N/A | -$162M | N/A | -$373M |
| 2025 | N/A | -$6.6M | -$858,263 | -$13.4M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2025 | $238M | -$6.8M |
| Dec 2025 | N/A | -$30.8M |
| Mar 2026 | N/A | -$18.9M |
| Jun 2026 | N/A | -$18.9M |
| Insider Ownership | 14.3% |
|---|---|
| Institutional Ownership | 34.2% |
| Short Float | 5.6% |
| % of All Funds Holding | 0.56% |
| Number of Funds Holding | 49 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $1.66 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $2.29 | Medium-term trend |
| Weekly | 80-Week SMA | $2.69 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $2.35 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $2.15 | Near-term monthly trend |
| Monthly | 20-Month SMA | $2.48 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $1.99 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 0.79% | 0.20% | 50.00% | 8.37% | -6.85% |
| 1 Day | 1.33% | 1.47% | 68.75% | 7.82% | -6.85% |
| 1 Week | 1.99% | -0.70% | 50.00% | 39.31% | -12.75% |
| 2 Weeks | 2.16% | -3.51% | 43.75% | 44.63% | -24.38% |
| 1 Month | 9.20% | -3.68% | 40.00% | 163.28% | -18.47% |
Next earnings: November 8, 2026 (29 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | -0.21% | 45.1% | 315 |
| Tuesday | 0.36% | 48.1% | 349 |
| Wednesday | 0.54% | 47.6% | 347 |
| Thursday | -0.46% | 41.0% | 339 |
| Friday | -0.11% | 41.7% | 336 |
Institutional holder breakdown coming soon.
Total institutional ownership: 34.2%
Total insider ownership: 14.3%
| Total Filings | 4 |
|---|---|
| Net Value | -$92,316.54 |
| Net Shares Change | -78,445 |
| % of Float | -0.1% |
| C-Suite Filings | 4 |
| Clusters Detected | 0 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Cao Sean Wuxiong | Chief Bus. Development Officer | -$79,903.72 | 1 | 1 sell |
| Xu Cong Claire | EVP, Clinical Development | -$6,584.43 | 2 | 2 sell |
| Dennis Phillip Andrew | Chief Medical Officer | -$5,828.39 | 1 | 1 sell |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-09-11 | Cao Sean Wuxiong | Chief Bus. Development Officer | -$79,903.72 | Transaction at $0.74, now +85.1% |
| 2026-09-21 | Dennis Phillip Andrew | Chief Medical Officer | -$5,828.39 | Transaction at $0.71, now +93.0% |
| 2026-09-01 | Xu Cong Claire | EVP, Clinical Development | -$2,592.78 | Transaction at $0.79, now +73.4% |
| 2026-07-07 | Xu Cong Claire | SVP, Clinical Development | -$3,991.65 | Transaction at $0.89, now +53.9% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for NovaBridge Biosciences (NBP) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for NBP on Trend Edge →